Traws Pharma (TRAW)
Develops oral antivirals for influenza and COVID-19.
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results and provided recent business highlights for the quarter ended June 30, 2026, including updates on its lead clinical programs and April 2026 financing.
Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shares shot up 4.8% during mid-day trading on Monday. The stock traded as high as $0.4871 and last traded at $0.4716. Approximately 94,244 shares were traded during trading, a decline of 31% from the average daily volume of 137,096 shares. The stock had previously closed at
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
Traws Pharma Provides Regulatory Update on Influenza Program
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent in its portfolio.
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to advance potential clinical candidates for the treatment of hantavirus infections.
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Traws Pharma (NASDAQ:TRAW) Shares Up 8.8% – Should You Buy?
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high as $1.64 and last traded at $1.61. 21,635 shares were traded during trading, a decline of 60% from the average session volume of 54,220 shares. The stock had previously closed at $1.48. Wall Street Analysts Forecast
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID ® -ineligible patients, representing a significant population with no effective treatment options
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID ®
Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - Interim CEO, Secretary & Director Robert R.
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM)